• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酸性鞘磷脂酶缺乏症中的癌症患病率。

Prevalence of Cancer in Acid Sphingomyelinase Deficiency.

作者信息

Mauhin Wladimir, Levade Thierry, Vanier Marie T, Froissart Roseline, Lidove Olivier

机构信息

Internal Medicine Department, Groupe Hospitalier Diaconesses Croix Saint Simon, 75020 Paris, France.

Metabolic Biochemistry Laboratory, Reference Center for Hereditary Metabolic Disorders, Biology Institute, Toulouse University Hospital, 31000 Toulouse, France.

出版信息

J Clin Med. 2021 Oct 28;10(21):5029. doi: 10.3390/jcm10215029.

DOI:10.3390/jcm10215029
PMID:34768550
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8584997/
Abstract

Acid sphingomyelinase deficiency (ASMD) is an inherited lysosomal disease characterised by a diffuse accumulation of sphingomyelin that cannot be catabolised into ceramide and phosphocholine. We studied the incidence of cancer in ASMD patients. We retrospectively reviewed the medical records of the adult chronic visceral ASMD patients in our cohort. Thirty-one patients (12 females, 19 males) were included with a median age of 48.7 y. (IQ: 30.3-55.1). Five cancers were observed in 1 female (breast cancer) and 4 males (two lung cancers, one thyroid cancer and one bladder cancer), resulting in a prevalence of 16.1%. The existence of cancer was associated with a more severe ASMD characterised by a larger spleen (25 cm (22.5-25) vs. 18 cm (17-20); = 0.042); lower diffusing capacity of the lung for carbon monoxide (DLCO; 29.5 % (17.8-43.0) vs. 58.5 % (49.8-69.5%); = 0.01) and tobacco use (100% vs. 45%; = 0.04). Three patients died, all from cancer ( = 0.002). The prevalence of cancer appeared to be strikingly elevated in our cohort of patients, without any specificity in the type of cancer. Systematic screening for cancer should be performed, and carcinogenic substances such as tobacco should be avoided in patients with ASMD.

摘要

酸性鞘磷脂酶缺乏症(ASMD)是一种遗传性溶酶体疾病,其特征是鞘磷脂弥漫性积聚,无法分解为神经酰胺和磷酸胆碱。我们研究了ASMD患者的癌症发病率。我们回顾性分析了我们队列中成年慢性内脏型ASMD患者的病历。纳入了31例患者(12例女性,19例男性),中位年龄为48.7岁(四分位间距:30.3 - 55.1)。在1例女性(乳腺癌)和4例男性(2例肺癌、1例甲状腺癌和1例膀胱癌)中观察到5例癌症,患病率为16.1%。癌症的存在与更严重的ASMD相关,其特征为脾脏更大(25 cm(22.5 - 25)vs. 18 cm(17 - 20);P = 0.042);肺一氧化碳弥散量(DLCO)更低(29.5%(17.8 - 43.0)vs. 58.5%(49.8 - 69.5%);P = 0.01)以及吸烟(100% vs. 45%;P = 0.04)。3例患者死亡,均死于癌症(P = 0.002)。在我们的患者队列中,癌症患病率似乎显著升高,且癌症类型无特异性。应对ASMD患者进行系统性癌症筛查,并且应避免他们接触烟草等致癌物质。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed52/8584997/ee2c59e96c79/jcm-10-05029-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed52/8584997/a4081e8f1140/jcm-10-05029-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed52/8584997/ee2c59e96c79/jcm-10-05029-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed52/8584997/a4081e8f1140/jcm-10-05029-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed52/8584997/ee2c59e96c79/jcm-10-05029-g002.jpg

相似文献

1
Prevalence of Cancer in Acid Sphingomyelinase Deficiency.酸性鞘磷脂酶缺乏症中的癌症患病率。
J Clin Med. 2021 Oct 28;10(21):5029. doi: 10.3390/jcm10215029.
2
Clinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy.临床试验终点在酸性鞘磷脂酶缺乏症酶替代治疗中的临床意义。
Mol Genet Metab. 2020 Sep-Oct;131(1-2):116-123. doi: 10.1016/j.ymgme.2020.06.008. Epub 2020 Jun 24.
3
Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann-Pick disease type B and B variant): Literature review and report of new cases.慢性内脏型和慢性神经内脏型酸性鞘磷脂酶缺乏症(尼曼-匹克病B型和B变异型)患者的死因:文献综述及新病例报告
Mol Genet Metab. 2016 Jul;118(3):206-213. doi: 10.1016/j.ymgme.2016.05.001. Epub 2016 May 11.
4
Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation.前瞻性研究儿童和成人慢性酸性鞘磷脂酶缺乏症的自然病史:十一年观察。
Orphanet J Rare Dis. 2021 May 10;16(1):212. doi: 10.1186/s13023-021-01842-0.
5
Glycoprotein non-metastatic protein B (GPNMB) plasma values in patients with chronic visceral acid sphingomyelinase deficiency.慢性内脏酸性鞘磷脂酶缺乏症患者的糖蛋白非转移性蛋白 B(GPNMB)血浆值。
Mol Genet Metab. 2023 Aug;139(4):107631. doi: 10.1016/j.ymgme.2023.107631. Epub 2023 Jul 9.
6
Chronic visceral acid sphingomyelinase deficiency (Niemann-Pick disease type B) in 16 Polish patients: long-term follow-up.慢性内脏酸性鞘磷脂酶缺乏症(尼曼-匹克病 B 型)在 16 名波兰患者中的长期随访。
Orphanet J Rare Dis. 2019 Feb 22;14(1):55. doi: 10.1186/s13023-019-1029-1.
7
Plasma lyso-sphingomyelin levels are positively associated with clinical severity in acid sphingomyelinase deficiency.在酸性鞘磷脂酶缺乏症中,血浆溶血鞘磷脂水平与临床严重程度呈正相关。
Mol Genet Metab Rep. 2021 Jul 7;28:100780. doi: 10.1016/j.ymgmr.2021.100780. eCollection 2021 Sep.
8
Healthcare Service Use Patterns Among Patients with Acid Sphingomyelinase Deficiency Type B: A Retrospective US Claims Analysis.患有酸性鞘磷脂酶缺乏症 B 型患者的医疗服务使用模式:一项美国回顾性理赔分析。
Adv Ther. 2023 May;40(5):2234-2248. doi: 10.1007/s12325-023-02453-w. Epub 2023 Mar 10.
9
Acid Sphingomyelinase Deficiency: Sharing Experience of Disease Monitoring and Severity in France.酸性鞘磷脂酶缺乏症:法国疾病监测与严重程度的经验分享
J Clin Med. 2022 Feb 10;11(4):920. doi: 10.3390/jcm11040920.
10
Similarities and differences between Gaucher disease and acid sphingomyelinase deficiency: An algorithm to support the diagnosis.戈谢病与酸性鞘磷脂酶缺乏症之间的异同:一种辅助诊断的算法
Eur J Intern Med. 2023 Feb;108:81-84. doi: 10.1016/j.ejim.2022.11.028. Epub 2022 Nov 26.

引用本文的文献

1
Oncological Aspects of Lysosomal Storage Diseases.溶酶体贮积症的肿瘤学方面。
Cells. 2024 Oct 8;13(19):1664. doi: 10.3390/cells13191664.
2
Acid sphingomyelinase deficiency in France: a retrospective survival study.法国酸性鞘磷脂酶缺乏症:一项回顾性生存研究。
Orphanet J Rare Dis. 2024 Aug 5;19(1):289. doi: 10.1186/s13023-024-03234-6.
3
Genetics of enzymatic dysfunctions in metabolic disorders and cancer.代谢紊乱和癌症中酶功能障碍的遗传学

本文引用的文献

1
Plasma lyso-sphingomyelin levels are positively associated with clinical severity in acid sphingomyelinase deficiency.在酸性鞘磷脂酶缺乏症中,血浆溶血鞘磷脂水平与临床严重程度呈正相关。
Mol Genet Metab Rep. 2021 Jul 7;28:100780. doi: 10.1016/j.ymgmr.2021.100780. eCollection 2021 Sep.
2
Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation.前瞻性研究儿童和成人慢性酸性鞘磷脂酶缺乏症的自然病史:十一年观察。
Orphanet J Rare Dis. 2021 May 10;16(1):212. doi: 10.1186/s13023-021-01842-0.
3
Cancer stem cells and ceramide signaling: the cutting edges of immunotherapy.
Front Oncol. 2023 Aug 2;13:1230934. doi: 10.3389/fonc.2023.1230934. eCollection 2023.
4
Cell-intrinsic ceramides determine T cell function during melanoma progression.细胞内神经酰胺决定黑色素瘤进展过程中 T 细胞的功能。
Elife. 2022 Nov 25;11:e83073. doi: 10.7554/eLife.83073.
5
Potential Role of Sphingolipidoses-Associated Lysosphingolipids in Cancer.鞘脂贮积症相关溶血鞘脂类在癌症中的潜在作用。
Cancers (Basel). 2022 Oct 5;14(19):4858. doi: 10.3390/cancers14194858.
6
Mortality in patients with alpha-mannosidosis: a review of patients' data and the literature.α-甘露糖苷贮积症患者的死亡率:患者数据和文献回顾。
Orphanet J Rare Dis. 2022 Jul 23;17(1):287. doi: 10.1186/s13023-022-02422-6.
7
Targeting Sphingolipid Metabolism as a Therapeutic Strategy in Cancer Treatment.靶向鞘脂代谢作为癌症治疗的一种策略
Cancers (Basel). 2022 Apr 27;14(9):2183. doi: 10.3390/cancers14092183.
8
Acid Sphingomyelinase Deficiency: Sharing Experience of Disease Monitoring and Severity in France.酸性鞘磷脂酶缺乏症:法国疾病监测与严重程度的经验分享
J Clin Med. 2022 Feb 10;11(4):920. doi: 10.3390/jcm11040920.
癌症干细胞与神经酰胺信号:免疫治疗的前沿领域。
Mol Biol Rep. 2020 Oct;47(10):8101-8111. doi: 10.1007/s11033-020-05790-z. Epub 2020 Sep 3.
4
Long-term efficacy of olipudase alfa in adults with acid sphingomyelinase deficiency (ASMD): Further clearance of hepatic sphingomyelin is associated with additional improvements in pro- and anti-atherogenic lipid profiles after 42 months of treatment.阿加糖酶β治疗酸性鞘磷脂酶缺乏症(ASMD)成人患者的长期疗效:42 个月治疗后,肝脏神经鞘磷脂进一步清除与前、后抗动脉粥样硬化脂质谱的进一步改善相关。
Mol Genet Metab. 2020 Sep-Oct;131(1-2):245-252. doi: 10.1016/j.ymgme.2020.06.010. Epub 2020 Jun 24.
5
Clinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy.临床试验终点在酸性鞘磷脂酶缺乏症酶替代治疗中的临床意义。
Mol Genet Metab. 2020 Sep-Oct;131(1-2):116-123. doi: 10.1016/j.ymgme.2020.06.008. Epub 2020 Jun 24.
6
Control of CD1d-restricted antigen presentation and inflammation by sphingomyelin.鞘磷脂调控 CD1d 限制性抗原呈递和炎症反应
Nat Immunol. 2019 Dec;20(12):1644-1655. doi: 10.1038/s41590-019-0504-0. Epub 2019 Oct 21.
7
Bioactive Sphingolipids as Biomarkers Predictive of Disease Severity and Treatment Response in Cancer: Current Status and Translational Challenges.生物活性鞘脂作为预测癌症疾病严重程度和治疗反应的生物标志物:现状与转化挑战
Anticancer Res. 2019 Jan;39(1):41-56. doi: 10.21873/anticanres.13078.
8
Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD).酸鞘磷脂酶缺乏症(ASMD)患者临床监测建议。
Mol Genet Metab. 2019 Feb;126(2):98-105. doi: 10.1016/j.ymgme.2018.11.014. Epub 2018 Nov 29.
9
CD4+ Foxp3+ regulatory T cell-mediated immunomodulation by anti-depressants inhibiting acid sphingomyelinase.抗抑郁药通过抑制酸性鞘磷脂酶介导 CD4+Foxp3+调节性 T 细胞的免疫调节作用。
Biol Chem. 2018 Sep 25;399(10):1175-1182. doi: 10.1515/hsz-2018-0159.
10
Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months.阿加糖酶α治疗酸性鞘磷脂酶缺乏症(ASMD):30 个月治疗成人的安全性和疗效。
J Inherit Metab Dis. 2018 Sep;41(5):829-838. doi: 10.1007/s10545-017-0123-6. Epub 2018 Jan 5.